

# Nab2 regulates secondary CD8<sup>+</sup> T-cell responses through control of TRAIL expression

Monika C. Wolkers,<sup>1,2</sup> Carmen Gerlach,<sup>3</sup> Ramon Arens,<sup>1</sup> Edith M. Janssen,<sup>4</sup> Patrick Fitzgerald,<sup>5</sup> Ton N. Schumacher,<sup>3</sup> Jan Paul Medema,<sup>2</sup> \*Douglas R. Green,<sup>5</sup> and \*Stephen P. Schoenberger<sup>1</sup>

<sup>1</sup>Laboratory of Cellular Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA; <sup>2</sup>Laboratory of Experimental Oncology and Radiobiology/Center of Experimental Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; <sup>3</sup>Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>4</sup>Division of Molecular Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and <sup>5</sup>Department of Immunology, St Jude Children's Research Hospital, Memphis, TN

CD4<sup>+</sup> Th cells are pivotal for the generation and maintenance of CD8<sup>+</sup> T-cell responses. "Helped" CD8<sup>+</sup> T cells receive signals during priming that prevent the induction of the proapoptotic molecule TNF-related apoptosis-inducing ligand (TRAIL) during reactivation, thereby enabling robust secondary expansion. Conversely, "helpless" CD8<sup>+</sup> T cells primed in the absence of Th induce TRAIL expression after restimulation and undergo activation-induced cell death. In the pres-

ent study, we investigated the molecular basis for the differential regulation of TRAIL in helped versus helpless CD8<sup>+</sup> T cells by comparing their transcriptional profiles, and have identified a transcriptional corepressor, NGFI-A binding protein 2 (Nab2), that is selectively induced in helped CD8<sup>+</sup> T cells. Enforced expression of Nab2 prevents TRAIL induction after restimulation of primary helpless CD8<sup>+</sup> T cells, and expression of a dominant-negative form of Nab2 in helped

CD8<sup>+</sup> T cells impairs their secondary proliferative response that is reversible by TRAIL blockade. Finally, we observe that the CD8<sup>+</sup> T-cell autocrine growth factor IL-2 coordinately increases Nab2 expression and decreases TRAIL expression. These findings identify Nab2 as a mediator of Th-dependent CD8<sup>+</sup> T-cell memory responses through the regulation of TRAIL and the promotion of secondary expansion, and suggest a mechanism through which this operates. (*Blood*. 2012;119(3):798-804)

## Introduction

Cytotoxic CD8<sup>+</sup> T cells play a fundamental role in the defense against viral and intracellular bacterial infections through the generation of early effectors that eradicate infected cells and of long-lived memory cells that confer durable protection against recurring infection.<sup>1-3</sup> CD4<sup>+</sup> Th cells influence the generation and maintenance of CD8<sup>+</sup> T-cell responses at several levels. This includes the recruitment of naive cells to dendritic cells within lymph nodes during priming, insuring their survival after primary expansion and facilitating the migration of effector cells into peripheral sites of Ag re-encounter.<sup>4,7</sup> In addition to these functions, Th cells are instrumental in the generation of CD8<sup>+</sup> T-cell memory through activation of APCs via CD40L-CD40 interactions to a state in which they can prime CD8<sup>+</sup> T cells capable of secondary expansion after Ag reencounter (reviewed by Bevan<sup>8</sup>). Several studies have demonstrated that this process involves modification of the differentiation program in CD8<sup>+</sup> T cells by signals received during the initial Ag encounter, resulting in specific patterns of gene expression in their daughter cells.<sup>9-11</sup> The clonal progeny of helpless CD8<sup>+</sup> T cells, for example, induce the proapoptotic molecule TNF-related apoptosis-inducing ligand (TRAIL) and its receptor (DR5) after restimulation, and subsequently undergo activation-induced cell death (AICD).<sup>12-14</sup> Helped CD8<sup>+</sup> T cells, in contrast, do not induce TRAIL expression after restimulation, and instead undergo the robust secondary T-cell responses associated with immune memory.<sup>13</sup>

In the present study, we investigated the molecular mechanisms regulating TRAIL expression in CD8<sup>+</sup> T cells by comparing the transcriptional profile of reactivated helped versus helpless CD8<sup>+</sup> T cells. This led to the identification of a transcriptional corepressor of TRAIL expression, NGFI-binding protein 2 (Nab2),<sup>15</sup> which is selectively induced in helped, but not helpless, CD8<sup>+</sup> T cells after restimulation. Exogenous expression of Nab2 effectively suppressed the induction of TRAIL in restimulated helpless CD8<sup>+</sup> T cells, and inhibition of Nab2 function in helped CD8<sup>+</sup> T cells prevented their ability to undergo secondary expansion, and this could be restored by blockade of TRAIL. Lastly, we found that the addition of IL-2, a key autocrine factor that can rescue the secondary response defect in helpless CD8<sup>+</sup> T cells, can induce Nab2 expression and prevent TRAIL. These data identify Nab2 as a molecular mediator of Th-dependent CD8<sup>+</sup> T-cell memory through regulation of TRAIL expression.

## Methods

### Mice and cell culture

C57BL/6J mice were purchased from The Jackson Laboratory. TCR-transgenic OT-I mice and C57BL/6J recipient mice were bred in-house. All animal experiments were performed in accordance with institutional and national guidelines of all participating institutions.

Submitted August 23, 2011; accepted November 13, 2011. Prepublished online as *Blood* First Edition paper, November 29, 2011; DOI 10.1182/blood-2011-08-373910.

\*D.R.G. and S.P.S. share senior authorship.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2012 by The American Society of Hematology

All cells were cultured in IMDM (GIBCO-BRL) supplemented with 8% FCS, 50  $\mu$ M 2-mercaptoethanol, 2mM L-glutamine, 20 U/mL of penicillin, and 20  $\mu$ g/mL of streptomycin.

### Generation of in vivo primed polyclonal CD8<sup>+</sup> T cells

Helped and helpless E1B<sub>192-200</sub>-specific CD8<sup>+</sup> T cells were generated as described previously.<sup>16</sup> Briefly, C57BL/6J mice were treated with 100  $\mu$ g of GK1.5 administered intraperitoneally (helpless) or were left untreated (helped) before subcutaneous immunization with  $1 \times 10^7$  irradiated (3000 rad) TAP<sup>-/-</sup>Ad5E1-MEC. Three days after immunization, all mice were treated with 100  $\mu$ g of GK1.5. Spleens and draining lymph nodes were harvested 7 days after immunization, and CD8<sup>+</sup> T cells were purified with the CD8 negative isolation kit (Miltenyi Biotec) according to the manufacturer's protocol. Purity was 88%-95%.

### Microarray and data analysis

Purified CD8<sup>+</sup> T cells from helped and helpless mice were sorted on CD44<sup>hi</sup> expression by flow cytometry. Cells were restimulated for 4 hours with 2  $\mu$ g/mL of E1B<sub>192-200</sub> peptide in the presence of 20  $\mu$ M qVD-OPh (R&D Systems). RNA was extracted using TRIzol reagent (Gibco BRL) according to the manufacturer's instructions. Five micrograms of total RNA was used to generate cDNA with RT Superscript III (Invitrogen). cDNA was labeled indirectly using cyanine 3 and cyanine 5 (Amersham). Labeled samples were purified and spotted in an equimolar ratio on the Mouse Exonic Evidence Based Oligonucleotide (MEEBO) array. Images were preview scanned on an Axon 4000B and channels were balanced until an overall Cy5/Cy3 ratio of 1 was achieved before a final data scan at 5  $\mu$ m was performed in GenePix. The images were manually gridded, and then saved for analysis. Data were analyzed using the Spotfire Decision Site.

Gene Ontology terms were downloaded from BioMart (www.biomart.org, Version NCBI37, April 9, 2009). Genes with Biologic Process term "regulation of transcription" (GO:0045449) were assumed to encode transcription factors. Of 276 probes with an absolute log2 ratio > 2, 231 probes were present in BioMart; the remaining cDNA probes did not match currently known genes. All microarray data are available at the Gene Expression Omnibus (GEO) under accession number GSE33862.

### Real-time RT-PCR

Purified CD8<sup>+</sup> T cells were restimulated with 2  $\mu$ g/mL of E1B<sub>192-200</sub> peptide for 4 hours or were left untreated. Where indicated, 20 CU/mL of human recombinant IL-2 was added during peptide restimulation. Cells were washed twice with PBS before total RNA was isolated using TRIzol reagent according to the manufacturer's protocol. RNA was reverse transcribed with RT SuperScript II (Invitrogen) using random hexamers (GIBCO-BRL) in the presence of RNaseOUT (Invitrogen). Sequence-specific primers for murine IFN $\gamma$ , TRAIL, Nab2, L32, and 18S were described previously.<sup>17</sup> Real-time RT-PCR was performed in a Bio-Rad iQ5 thermal cycler using the SyBr Green detection protocol as outlined by the manufacturer (Abgene). L32 and 18S were used as internal controls.

### Plasmids, transfections, and retroviral transductions

Murine Nab2 cDNA (BC045139; Open Biosystems) was cloned into pcDNA3.1 to generate pcDNA3.1-Nab2. Nab2<sub>E51K</sub> was generated with site-directed mutagenesis according to the manufacturer's protocol (Promega) and cloned into pMIG to generate pMIG-Nab2<sub>E51K</sub>. Sequences were confirmed by sequence analysis.

For exogenous expression of Nab2 in helpless CD8<sup>+</sup> T cells,  $10 \times 10^6$  cells were transfected with 2  $\mu$ g of pcDNA3.1-Nab2 or the empty pcDNA3.1 control, together with 0.5  $\mu$ g of pmaxGFP according to the manufacturer's protocol (Amaya). At 24 hours after transfection, cells were harvested and restimulated with 2  $\mu$ g/mL of E1B<sub>192-200</sub> peptide for 4 hours or were left untreated before RNA isolation.

The production of retrovirus containing pMIG-NAB2<sub>E51K</sub> or pMIG-EV for the transduction of OT-I thymocytes was performed as described previously.<sup>18</sup>

### T-cell transfer of naive NAB2<sub>E51K</sub>-expressing OT-I T cells

OT-I Ly5.1 thymocytes were retrovirally transduced with pMIG-NAB2<sub>E51K</sub>, or pMIG-EV, as described previously.<sup>18</sup> Twenty-four hours after retroviral transduction,  $0.5-1 \times 10^6$  green fluorescent protein (GFP)-sorted OT-I thymocytes were transferred intrathymically into C57BL/6 carrier mice. Two weeks after transfer, spleens and lymph nodes were collected and CD8<sup>+</sup> T cells were purified (Mouse CD8 T Lymphocyte Enrichment Set; BD Biosciences). Approximately  $2 \times 10^6$  CD8<sup>+</sup> T cells containing 60 GFP<sup>+</sup> OT-I cells were transferred into C57BL/6J mice. The fraction of transferred GFP-expressing OT-I cells within the isolated CD8<sup>+</sup> T cells was confirmed by flow cytometry. The next day, experimental mice received 100  $\mu$ g of GK1.5 IP or were left untreated, and 3 days later, they were immunized with  $2 \times 10^6$  irradiated (1500 rad) OVA-coated splenocytes as described previously.<sup>19</sup> All mice were treated with GK1.5 3 days after immunization. Spleens and lymph nodes were harvested 7 days after immunization, and the number of OVA<sub>257-264</sub>-specific CD8<sup>+</sup> T cells (GFP<sup>+</sup> and GFP<sup>-</sup>) was determined by Kb-OVA<sub>257-264</sub> tetramer staining. To assess the fold expansion of OVA<sub>257-264</sub>-specific CD8<sup>+</sup> T cells, the absolute number of Kb-OVA<sub>257-264</sub> tetramer<sup>+</sup> CD8<sup>+</sup> T cells obtained after 7 days in vitro culture with irradiated (3000 rad) MEC.B7.SigOVA cells in a ratio of 40:1 was divided by the absolute number of Kb-OVA<sub>257-264</sub> tetramer<sup>+</sup> CD8<sup>+</sup> T cells placed into culture, as described previously.<sup>16</sup> For blocking studies, CD8<sup>+</sup> T cells were sorted by CD8 negative selection (Miltenyi Biotec) before in vitro restimulation with MEC.B7.SigOVA cells in a effector:stimulator ratio of 25:1 in the presence of 5  $\mu$ g/mL of murine TRAIL-R-FC or Fas-FC (R&D Systems) or 20 CU of recombinant human IL-2.

### Flow cytometry and analysis

mAbs against CD8, CD44, and IFN $\gamma$  (BD Pharmingen and eBioscience) were used for flow cytometry. Kb-OVA<sub>257-264</sub> tetramers were generated as described previously.<sup>20</sup> For intracellular cytokine staining,  $1-1.5 \times 10^6$  cells were cultured in the absence or presence of 2  $\mu$ g/mL E1B<sub>192-200</sub> peptide or 1  $\mu$ g/mL of OVA<sub>257-264</sub> and brefeldin A for 5 hours at 37°C. After surface Ab staining, cells were fixed and permeabilized for intracellular IFN $\gamma$  staining according to the manufacturer's protocol (BD Pharmingen). Flow cytometry samples were acquired on a FACScalibur instrument (BD Biosciences) and analyzed using FlowJo Version 8 software (TreeStar).


### Statistical analysis

Data are expressed as means  $\pm$  SD and were evaluated using ANOVA followed by a Dunnett test. Data analyzing the fold induction of Nab2 (Figure 1C), and TRAIL (Figure 2D) were analyzed with the Mann-Whitney test.  $P < .05$  was considered statistically significant.

## Results

### Differential expression of Nab2 in helped versus helpless CD8<sup>+</sup> T cells

To elucidate how TRAIL expression is regulated in helped versus helpless CD8<sup>+</sup> T cells, we first sought to identify the molecular regulators that are differentially expressed on secondary antigenic challenge. To this end, Ag-specific CD8<sup>+</sup> T cells were generated using an established cross-priming model (TAP<sup>-/-</sup>Ad5E1-MEC) that has been shown previously to induce a CD4-dependent secondary CD8<sup>+</sup> T-cell response specific for the immunodominant epitope (E1B<sub>192-200</sub>).<sup>16,21</sup> Eight days after immunization of CD4-depleted (helpless) or intact (helped) mice, spleens and lymph nodes were harvested and CD8<sup>+</sup> T cells were isolated by positive selection. Ag-experienced CD8<sup>+</sup> T cells were further enriched for CD44<sup>hi</sup> expression by flow cytometry. As assessed by intracellular IFN $\gamma$  staining after antigenic restimulation, we estimated an enrichment of E1B<sub>192-200</sub>-specific CD8<sup>+</sup> T cells of 30- to 50-fold with this isolation method (Figure 1A and data not shown). Using a



**Figure 1. Nab2 is differentially regulated in helped versus helpless CD8<sup>+</sup> T cells.** Splensins from TAP<sup>-/-</sup>Ad5E1-MEC-primed mice in a helped or helpless setting were harvested and CD8<sup>+</sup> T cells isolated. A CD44<sup>hi</sup> sort was performed on nonreactivated cells. (A) Purified CD8<sup>+</sup> T cells were restimulated for 4 hours with the E1B<sub>192-200</sub> peptide and intracellular IFN- $\gamma$  staining was performed. Nineteen percent and 10% IFN- $\gamma$ <sup>+</sup> cells for helped and helpless CD44<sup>hi</sup> CD8<sup>+</sup> T cells was measured, respectively. Gate represents sorting gate employed to enrich for CD44<sup>hi</sup> CD8<sup>+</sup> T cells. (B) Quantitative RT-PCR analysis of Nab2 mRNA levels in restimulated CD44<sup>hi</sup>-sorted CD8<sup>+</sup> T cells. (C) Helped and helpless CD8<sup>+</sup> T cells isolated from TAP<sup>-/-</sup>Ad5E1-MEC-primed mice were restimulated with the E1B<sub>192-200</sub> peptide or left untreated, and the fold induction of Nab2 transcripts was determined. Each connected dataset represents an independently performed experiment (n = 4; T cells were pooled from 4 mice per group). \*P < .05; \*\*P < .02.

selection method that did not involve TCR engagement, reactivation of the CD8<sup>+</sup> T cells during isolation was minimized.

The enriched helped and helpless CD8<sup>+</sup> T cells were then restimulated for 4 hours in vitro with the E1B<sub>192-200</sub> peptide, and

their transcriptional profile was analyzed with the Mouse Exonic Evidence Based Oligonucleotide (MEEBO) array platform.<sup>22</sup> Comparison of these transcriptional profiles revealed that 276 of 30 000 probes displayed a differential expression pattern of at least a 2-fold difference in helpless CD8<sup>+</sup> T cells compared with helped CD8<sup>+</sup> T cells (supplemental Table 1, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). Because our interest was in gene regulation of TRAIL, we focused on the 36 genes that were assigned to the category “regulation of transcription” by the BioMart gene ontology list.<sup>23</sup> Of these, 20 genes were up-regulated and 16 were down-regulated in helpless CD8<sup>+</sup> T cells compared with helped CD8<sup>+</sup> T cells (Table 1). We further examined transcriptional regulators implicated in cell survival. An intriguing candidate in this category was Nab2 (Table 1), because its homologous family member Nab1 has been shown to regulate several apoptosis genes, including TRAIL, in epithelial cells through interaction with the early growth response genes.<sup>17</sup> Using a semiquantitative RT-PCR approach, we confirmed that the expression of Nab2 was significantly reduced in reactivated helpless versus helped CD8<sup>+</sup> T cells (Figure 1B; P = .005). Furthermore, we found that Nab2 transcripts were increased by approximately 1.5- to 3-fold after antigenic restimulation of helped CD8<sup>+</sup> T cells. However, because we studied a polyclonal CD8<sup>+</sup> T-cell response that contained a mixture of Ag-specific and non-Ag-specific CD8<sup>+</sup> T cells, this number may be an underestimate. Helpless CD8<sup>+</sup> T cells, in contrast, failed to show induction of Nab2 expression (Figure 1C; P = .02). These data reveal that the presence of CD4<sup>+</sup> T-cell help during the priming of CD8<sup>+</sup> T cells positively modifies the expression pattern of Nab2 in their clonal progeny.

#### Nab2 blocks TRAIL expression in reactivated helpless CD8<sup>+</sup> T cells

Having correlated Nab2 with the absence of TRAIL expression in restimulated helped CD8<sup>+</sup> T cells, we next assessed whether forced expression of Nab2 could similarly regulate TRAIL induction in helpless cells. Freshly isolated helpless CD8<sup>+</sup> T cells from


**Table 1. Differential expression of transcription-regulating genes in reactivated helpless versus helped CD8<sup>+</sup> T cells**

Reference no.	Gene	Log <sub>2</sub> ratio	Reference no.	Gene	Log <sub>2</sub> ratio
NM_133208	<i>Zfp287</i>	-1.6074	NM_008950	<i>Psmc5</i>	1.0019
NM_145546	<i>Gtf2b</i>	-1.4275	NM_183298	<i>Foxe1</i>	1.0262
NM_011445	<i>Sox6</i>	-1.3916	NM_008391	<i>Irf2</i>	1.0305
NM_177338	<i>Hmbox1</i>	-1.3042	NM_009558	<i>Zfp51</i>	1.0320
NM_008668	<i>Nab2</i>	-1.2733	NM_010136	<i>Eomes</i>	1.0570
NM_172716	<i>Pcgf3</i>	-1.2002	NM_177888	<i>Zfp78</i>	1.0821
NM_008651	<i>Mybl1</i>	-1.1843	NM_177888	<i>Zfp78</i>	1.0821
NM_009986	<i>Cutl1</i>	-1.1471	NM_023434	<i>5730589K01Rik</i>	1.0865
NM_010432	<i>Hipk1</i>	-1.1431	NM_153287	<i>Axud1</i>	1.1372
NM_175477	<i>Zfp574</i>	-1.1397	NM_030676	<i>Nr5a2</i>	1.1422
NM_010731	<i>Zbtb7a</i>	-1.0740	NM_172495	<i>Ncoa7</i>	1.1723
NM_023266	<i>Zfp120</i>	-1.0630	NM_011050	<i>Pdcd4</i>	1.1815
NM_175247	<i>Zfp28</i>	-1.0398	NM_133966	<i>Taf5l</i>	1.1948
NM_011768	<i>Zfx</i>	-1.0305	NM_145455	<i>Btf3</i>	1.2371
NM_027063	<i>1700013G24Rik</i>	-1.0208	NM_010905	<i>Nfia</i>	1.3377
NM_201355	<i>BC047219</i>	-1.0031	NM_010411	<i>Hdac3</i>	1.3448
			NM_033552	<i>Slc4a10</i>	1.4431
			NM_017376	<i>Tef</i>	1.5242
			NM_183185	<i>D930016N04Rik</i>	1.6470
			NM_019935	<i>Ovol1</i>	1.7046
			NM_009372	<i>Tgif</i>	1.9097

Probes displaying an absolute log<sub>2</sub> ratio of > 1 were analyzed for genes with the annotation “regulation of transcription” (GO:0045449) by BioMart; Log<sub>2</sub> ratio > -1, lower expression in helpless CD8<sup>+</sup> T cells; log<sub>2</sub> ratio > 1, higher expression in helpless CD8<sup>+</sup> T cells.



**Figure 2. Nab2 blocks TRAIL induction in restimulated helpless CD8<sup>+</sup> T cells.** CD8<sup>+</sup> T cells were purified from TAP<sup>-/-</sup>Ad5E1-MEC-primed, helpless mice and were transfected with 2  $\mu$ g of pcDNA3.1-Nab2 or the empty control vector, together with 0.5  $\mu$ g of the reporter plasmid pMAX-GFP. (A) Twenty-four hours after transfection, GFP expression was determined as a measurement for transfection efficiency. (B-D) CD8<sup>+</sup> T cells were cultured for 4 hours in the presence or absence of the E1B<sub>192-200</sub> peptide, and the relative expression of TRAIL (B) and IFN $\gamma$  (D) mRNA was determined. (C) The fold induction of TRAIL in Nab2- or EV-transfected CD8<sup>+</sup> T cells was assessed by comparing mRNA levels before and after E1B<sub>192-200</sub> peptide restimulation. Each connected dataset represents an independently performed experiment (n = 4; T cells were pooled from 4 mice per group). \**P* < .05; \*\*\**P* < .005.



TAP<sup>-/-</sup>Ad5E1-MEC-immunized mice were transfected with an expression plasmid encoding Nab2 or control empty vector (EV), and assessed 24 hours later for TRAIL expression after reactivation with the cognate Ag (Figure 2). Strikingly, exogenous expression of Nab2 abolished the induction of TRAIL transcripts in helpless CD8<sup>+</sup> T cells after Ag encounter, in contrast to the marked induction of TRAIL mRNA detected in CD8<sup>+</sup> T cells transfected with the EV (Figure 2B-C, *P* = .0002 and *P* = .029, respectively). Nab2 expression did not appear to affect the overall functional response to antigenic stimuli, because both Nab2- and EV-transfected CD8<sup>+</sup> T cells displayed comparable levels of IFN $\gamma$  mRNA induction after secondary Ag encounter (Figure 2D). These results show that Nab2 can prevent the TRAIL induction that occurs after restimulation of helpless CD8<sup>+</sup> T cells.


#### A dominant-negative Nab2 (Nab2<sub>E51K</sub>) prevents the secondary expansion of helped CD8<sup>+</sup> T cells via TRAIL regulation

Because TRAIL deficiency rescues reactivated helpless CD8<sup>+</sup> T cells from AICD,<sup>12-14</sup> and because Nab2 potentially suppresses their induction of TRAIL (Figure 2B-C), we hypothesized that inhibition of endogenous Nab2 activity might interfere with the secondary proliferation response of helped CD8<sup>+</sup> T cells. To address this, we introduced a dominant-negative form of Nab2 (Nab2<sub>E51K</sub>) into OT-I transgenic CD8<sup>+</sup> T cells together with GFP on a bicistronic vector. Nab2<sub>E51K</sub> retains the ability to oligomerize with endogenous Nab proteins, but is incapable of interacting with, and thereby repressing, its binding partners, the Egr transactivators.<sup>24</sup> Because Th-cell-dependent programming of memory functions—including secondary expansion—occurs during the first days of CD8<sup>+</sup> T-cell priming, it was necessary that the Nab2<sub>E51K</sub>-expressing CD8<sup>+</sup> T cells be naive before their initial Ag encounter.<sup>9,16,25</sup> We therefore generated naive Nab2<sub>E51K</sub>- or EV-expressing primary OT-I T cells by retroviral transduction into OT-I thymocytes, followed by intrathymic transfer into new donor mice to allow for the completion of T-cell differentiation.<sup>18</sup> The peripheral OT-I/Nab2<sub>E51K</sub> cells

and OT-I/EV control cells displayed a naive T-cell phenotype, as assessed by their low-intermediate expression levels of CD44 and high expression levels of CD62L when harvested 2 weeks later from the spleens and lymph nodes of recipient mice (supplemental Figure 1).

Approximately 60 GFP<sup>+</sup>, OT-I/Nab2<sub>E51K</sub> or OT-I/EV T cells were transferred into naive recipients to obtain OT-I T-cell responses phenotypically comparable to the endogenous polyclonal repertoire.<sup>26,27</sup> Mice were immunized with OVA-coated splenocytes as described previously<sup>19</sup> in a helped or helpless setting, and 7 days later, the OVA<sub>257-264</sub>-specific T-cell responses in the spleens and lymph nodes were enumerated *ex vivo*. A portion of the spleen and lymph node populations were restimulated *in vitro* with MEC.B7.SigOVA cells and re-evaluated for OVA<sub>257-264</sub>-specific T cells, with the secondary proliferative response calculated by comparing the input and output number of OVA<sub>257-264</sub>-specific T cells.<sup>16</sup> Consistent with our finding that Nab2 represses the expression of TRAIL (Figure 2), blocking Nab2 function in helped OT-I T cells markedly reduced their secondary proliferative response (Figure 3A; *P* = .001). This defect was cell intrinsic for Nab2<sub>E51K</sub>-expressing OT-I T cells, because both the OT-I/EV T cells and the endogenous OVA<sub>257-264</sub>-specific CD8<sup>+</sup> T cells proliferated substantially after secondary Ag encounter in helped mice (Figure 3A-B). These data reveal that helped CD8<sup>+</sup> T cells require Nab2 function to mount an optimal secondary T-cell expansion.

We also sought to determine whether the mechanism through which Nab2<sub>E51K</sub> blocks secondary expansion in helped OT-I T cells involved TRAIL. To accomplish this, OT-I/Nab2<sub>E51K</sub> T cells were restimulated in the presence of a soluble form of the TRAIL receptor TRAIL-R-Fc, as described previously.<sup>13,28</sup> To preclude indirect effects of blocking TRAIL, CD8<sup>+</sup> T cells were purified before *in vitro* restimulation. After this treatment, the secondary expansion of OT-I/Nab2<sub>E51K</sub> cells was significantly reduced compared with OT-I-EV cells (supplemental Figure 2; *P* < .05). Strikingly, when TRAIL activity was blocked during restimulation,



**Figure 3. Nab2<sub>E51K</sub> affects CD8<sup>+</sup> T-cell expansion after restimulation mediated through TRAIL.** Sixty naive OTI T cells expressing Nab2<sub>E51K</sub> or the EV were transferred into C57BL/6J mice before immunization with OVA-loaded splenocytes in a helped or helpless setting. Seven days later, lymphocytes were harvested and the number of OVA<sub>257-264</sub>-specific T cells was determined by K<sup>b</sup>-OVA<sub>257-264</sub> tetramer staining. Cells were restimulated with MEC.B7.SigOVA cells for 7 days, and the number of OVA<sub>257-264</sub>-specific T cells was reassessed. The fold expansion was determined for (A) exogenous Nab2<sub>E51K</sub>-expressing or EV-expressing OT-I T cells (A) and for the corresponding endogenous OVA<sub>257-264</sub>-specific CD8<sup>+</sup> T-cell responses (B). Each data point represents an individual mouse or 2 pooled mice (n = 3). Graph shows data compiled from 3 individual experiments (GFP WT, n = 11; all other groups, n = 14). (C-D) CD8<sup>+</sup> T cells were isolated from helped and helpless mice that had received OT-I-Nab2<sub>E51K</sub> cells (C) or OT-I-EV cells (D) before immunization with OVA-coated splenocytes. CD8<sup>+</sup> T cells were restimulated with MEC.B7.SigOVA cells for 7 days in the presence of 5 μg/mL of TRAIL-Fc, 5 μg/mL of Fas-Fc, or 20 CU/mL of recombinant human IL-2 or medium alone (ctrl). The secondary proliferation of GFP<sup>+</sup> OTI T cells was assessed with Kb-OVA<sub>257-264</sub> tetramer staining, as described previously.<sup>23</sup> Secondary expansion of helped OTI-EV cells with Ag alone was significantly higher than that of Nab2<sub>E51K</sub>-expressing T cells (*P* < .05; supplemental Figure 2). Each data point represents T cells pooled from 2 mice; the figure depicts 3 biologic replicates. \*\**P* < .02; \*\*\**P* < .002.

the expansive capacity of OT-I/Nab2<sub>E51K</sub> T cells was restored (Figure 3C; *P* < .02), supporting our hypothesis that blocking Nab2 in helped CD8<sup>+</sup> T cells results in reduced secondary expansion because of TRAIL-mediated AICD. The effect of blocking TRAIL was similar to the rescue observed after IL-2 addition, which was shown previously to rescue secondary expansion of helpless CD8<sup>+</sup> T cells in part by interfering with TRAIL-mediated AICD<sup>13,28</sup> (Figure 3C; *P* < .02). A control fusion protein, Fas-Fc, failed to restore secondary responses (Figure 3C), and the addition of TRAIL-R-Fc did not significantly alter the expansion of OT-I/EV control-expressing T cells compared with the expansion in the presence of Ag alone (Figure 3D controls; *P* = .47). These data reveal that in the absence of Nab2 function, helped CD8<sup>+</sup> T cells undergo TRAIL-mediated AICD in a manner similar to helpless CD8<sup>+</sup> T cells that fail to induce Nab2.


#### IL-2 induces Nab2 expression in helpless CD8<sup>+</sup> T cells

We next investigated the factors that may govern the induction of Nab2 in reactivated CD8<sup>+</sup> T cells. Previous studies have demonstrated that CD8<sup>+</sup> T cells must receive IL-2 signals during priming to allow for secondary expansion after Ag re-encounter, and we and others have recently shown that CD8<sup>+</sup> T cells themselves are the source of this required cytokine.<sup>29,30</sup> In addition, IL-2 signaling restores the proliferative and functional capacity of helpless CD8<sup>+</sup> T cells after reactivation, and this occurs by inhibition of TRAIL expression.<sup>13,28</sup> We therefore speculated that the mechanism through which IL-2 prevents TRAIL-mediated AICD is through the induc-

tion of Nab2 expression. To address this, we investigated whether the addition of exogenous IL-2 at restimulation would prevent TRAIL induction in helpless E1B<sub>192-200</sub>-specific CD8<sup>+</sup> T cells. In the experiment shown in Figure 4A, helped CD8<sup>+</sup> T cells expressed low levels of TRAIL message *ex vivo*, and antigenic stimulation further suppressed TRAIL mRNA levels (*P* < .005). In contrast, helpless CD8<sup>+</sup> T cells rapidly up-regulated TRAIL message in response to Ag (*P* < .0001), which was inhibited by approximately 50% after the addition of 20 ng/mL of IL-2 during antigenic restimulation (*P* < .005). We then assessed whether IL-2 affects the expression of TRAIL via Nab2. Exogenous IL-2 increased the level of Nab2 transcripts in restimulated helpless CD8<sup>+</sup> T cells by approximately 4-fold (Figure 4B; *P* < .01). The addition of IL-2 was accompanied by an increase in IFN $\gamma$  transcripts in helpless CD8<sup>+</sup> T cells (Figure 4C), but did not increase Nab2 or IFN $\gamma$  transcription above the high basal levels found in restimulated helped CD8<sup>+</sup> T cells, suggesting that secondary Ag encounter sufficed for helped CD8<sup>+</sup> T cells to induce proficient effector T cells (Figure 4B-C). These data establish a link between IL-2 signaling and TRAIL expression in CD8<sup>+</sup> T cells that is mediated by Nab2.

## Discussion

The results of the present study demonstrate that the transcriptional regulator Nab2 suppresses TRAIL expression in reactivated CD8<sup>+</sup>



**Figure 4. IL-2 affects the transcriptional profile of TRAIL and Nab2 in helpless CD8<sup>+</sup> T cells.** Purified CD8<sup>+</sup> T cells isolated from helped (filled bars) or helpless mice (open bars) were restimulated with the E1B<sub>192-200</sub> peptide in the absence or presence of 20 CU/mL of recombinant human IL-2 or were left untreated. The relative mRNA expression of TRAIL (A), Nab2 (B), and IFN-γ (C) was determined by RT-PCR (T cells were pooled from 3–4 mice per group and data shown are representative of 3 experiments). \*\**P* < .02; \*\*\**P* < .005.

T cells, thereby allowing secondary proliferative responses to occur. Helpless CD8<sup>+</sup> T cells made to express Nab2 at secondary antigenic stimulation were able to avoid TRAIL induction. In addition, blockade of Nab2 function in helped CD8<sup>+</sup> T cells prevented the secondary proliferation that is a hallmark of the memory response, and instead directed them toward TRAIL-mediated AICD, as did their helpless counterparts. Lastly, we found that IL-2 induces Nab2 and prevents TRAIL induction in restimulated helpless CD8<sup>+</sup> T cells, thereby providing a mechanism for the recent findings on IL-2-mediated rescue of the helpless phenotype.<sup>13,28</sup> These results provide the first insights into the molecular components through which Th enables secondary expansion in CD8<sup>+</sup> T cells through regulation of TRAIL.

Previous studies examining the transcriptional regulation of helpless CD8<sup>+</sup> T cells identified T-bet as an attenuator of CD4<sup>+</sup> T-cell help during T-cell priming, thereby negatively affecting the effective memory T-cell development.<sup>31</sup> Furthermore, in vitro T-cell activation studies have shown that lack of CD4<sup>+</sup> T-cell help results in a diminished histone acetylation of the IFN-γ promoter that prevents the development of functional responses of helpless CD8<sup>+</sup> T cells.<sup>32,33</sup> In the present study, we describe Nab2 as a transcriptional regulator that manifests the effects of CD4<sup>+</sup> T-cell

help for CD8<sup>+</sup> T cells, allowing the development of secondary CD8<sup>+</sup> T-cell responses to occur. In support of this notion, we found that Nab2 can be induced by IL-2, which itself is required as an autocrine factor for CD8<sup>+</sup> T-cell memory.

A variety of cognate and cytokine signals have been proposed to be involved in communicating the “help message” during T-cell priming, including CD40-CD40L, CD28-CD80/86, CD27-CD70, and IL-2R signaling; however, which of these signals synergizes with TCR engagement to program Nab2 induction on recall is to date unclear.<sup>12,29,34–39</sup> A possible link with IL-2 is compelling, given our recent finding that autocrine IL-2 is critical for secondary expansion in helped CD8<sup>+</sup> T cells, and the present study’s demonstration that IL-2 can induce Nab2 and inhibit TRAIL in helpless CD8<sup>+</sup> T cells (Figure 4B). Interestingly, Nab2 can regulate the production of IL-2 in activated T cells, and both Nab2 and the transcription factor Egr-1 have been shown to interact with the IL-2 promoter in activated T cells.<sup>40,41</sup> These data suggest that Nab2 and IL-2 are components of a positive feedback loop through which Th signals provided during priming are integrated into the memory response of CD8<sup>+</sup> T cells through regulation of TRAIL-mediated AICD.

## Acknowledgments

The authors thank the staff of the flow cytometry facilities of the St Jude Children’s Research Hospital and the National Cancer Institute for cell sorting, the microarray facility of St Jude Children’s Research Hospital for performing the array, Dr M. Wang (St Jude Children’s Research Hospital) and Dr B. van Steensel (National Cancer Institute) for assisting with the analysis of microarray data, and Dr N. Droin for the RT-PCR primers.

This study was supported by grants from the National Institutes of Health (RO1 AI076972 and RO1CA81261 to S.P.S.), the Leukemia & Lymphoma Society (1630-06 to S.P.S.), the Cancer Research Institute/Irvington Fellowship, and the Dutch Science Foundation (VENI grant 916.76.127 to M.C.W.).

## Authorship

Contribution: M.C.W., C.G., E.M.J., D.R.G., T.N.S., J.P.M., and S.P.S. designed the experiments; M.C.W., C.G., R.A., E.M.J., and P.F. performed the experiments and analyzed the data; and M.C.W., D.R.G., and S.P.S. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for M.C.W. is Department of Hematopoiesis, Sanquin Research/Landsteiner Laboratory AMC, Amsterdam, The Netherlands.

Correspondence: M. Wolkers, Department of Hematopoiesis, Sanquin Research/Landsteiner Laboratory AMC, Plesmanlaan 125, 1066CX Amsterdam, The Netherlands; e-mail: m.wolkers@sanquin.nl.

## References

- Williams MA, Bevan MJ. Effector and memory CTL differentiation. *Annu Rev Immunol*. 2007;25:171–192.
- Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. *Immunity*. 2010;33(4):451–463.
- Cui W, Kaech SM. Generation of effector CD8<sup>+</sup> T cells and their conversion to memory T cells. *Immunol Rev*. 2010;236:151–166.
- Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. *Nature*. 2009;462(7272):510–513.
- Kumamoto Y, Mattei LM, Sellers S, Payne GW, Iwasaki A. CD4<sup>+</sup> T cells support cytotoxic T lymphocyte priming by controlling lymph node input. *Proc Natl Acad Sci U S A*. 2011;108(21):8749–8754.
- Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinacker C, Germain RN. Chemokines enhance immunity by guiding naive CD8<sup>+</sup> T cells to

- sites of CD4+ T cell-dendritic cell interaction. *Nature*. 2006;440(7086):890-895.
7. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. *Cancer Res*. 2010;70(21):8368-8377.
  8. Bevan MJ. Helping the CD8(+) T-cell response. *Nat Rev Immunol*. 2004;4(8):595-602.
  9. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. *Nat Immunol*. 2001;2(5):423-429.
  10. van Stipdonk MJ, Hardenberg G, Bijker MS, et al. Dynamic programming of CD8+ T lymphocyte responses. *Nat Immunol*. 2003;4(4):361-365.
  11. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming in memory T-cell development. *Curr Opin Immunol*. 2004;16(2):217-225.
  12. Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. *Proc Natl Acad Sci U S A*. 2008;105(13):5201-5206.
  13. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature*. 2005;434(7029):88-93.
  14. Barker BR, Gladstone MN, Gillard GO, Panas MW, Letvin NL. Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. *Eur J Immunol*. 2010;40(11):3085-3096.
  15. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. *Mol Cell Biol*. 1996;16(7):3545-3553.
  16. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. *Nature*. 2003;421(6925):852-856.
  17. Droin NM, Pinkoski MJ, Dejardin E, Green DR. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. *Mol Cell Biol*. 2003;23(21):7638-7647.
  18. Gerlach C, van Heijst JW, Swart E, et al. One naive T cell, multiple fates in CD8+ T cell differentiation. *J Exp Med*. 2010;207(6):1235-1246.
  19. Carbone FR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. *J Exp Med*. 1990;171(2):377-387.
  20. Haanen JB, Toebes M, Cordaro TA, Wolkers MC, Kruisbeek AM, Schumacher TN. Systemic T cell expansion during localized viral infection. *Eur J Immunol*. 1999;29(4):1168-1174.
  21. Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. *J Immunol*. 1998;161(8):3808-3812.
  22. Verdugo RA, Medrano JF. Comparison of gene coverage of mouse oligonucleotide microarray platforms. *BMC Genomics*. 2006;7:58.
  23. Haider S, Ballester B, Smedley D, Zhang J, Rice P, Kasprzyk A. BioMart Central Portal—unified access to biological data. *Nucleic Acids Res*. 2009;37:W23-27.
  24. Svaren J, Sevetson BR, Golda T, Stanton JJ, Swirnow AH, Milbrandt J. Novel mutants of NAB corepressors enhance activation by Egr transactivators. *EMBO J*. 1998;17(20):6010-6019.
  25. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. *Nat Immunol*. 2001;2(5):415-422.
  26. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. *Nat Immunol*. 2005;6(8):793-799.
  27. Badovinac VP, Haring JS, Harty JT. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. *Immunity*. 2007;26(6):827-841.
  28. Wolkers MC, Bensinger SJ, Green DR, Schoenberger SP, Janssen EM. Interleukin-2 rescues helpless effector CD8(+) T cells by diminishing the susceptibility to TRAIL mediated death. *Immunol Lett*. 2011;139(1-2):25-32.
  29. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. *Nature*. 2006;441(7095):890-893.
  30. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. *Nat Immunol*. 2011;12(9):908-913.
  31. Intlekofer AM, Takemoto N, Kao C, et al. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. *J Exp Med*. 2007;204(9):2015-2021.
  32. Northrop JK, Wells AD, Shen H. Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells. *J Immunol*. 2008;181(2):865-868.
  33. Northrop JK, Thomas RM, Wells AD, Shen H. Epigenetic remodeling of the IL-2 and IFN-gamma loci in memory CD8 T cells is influenced by CD4 T cells. *J Immunol*. 2006;177(2):1062-1069.
  34. Wilson EB, Livingstone AM. Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. *J Immunol*. 2008;181(11):7445-7448.
  35. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature*. 1998;393(6684):480-483.
  36. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. *Science*. 1996;271(5256):1723-1726.
  37. Prilliman KR, Lemmens EE, Palioungas G, et al. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. *J Immunol*. 2002;169(8):4094-4097.
  38. Matter MS, Claus C, Ochsenbein AF. CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression. *Eur J Immunol*. 2008;38(7):1847-1856.
  39. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature*. 1998;393(6684):478-480.
  40. Skerka C, Decker EL, Zipfel PF. A regulatory element in the human interleukin 2 gene promoter is a binding site for the zinc finger proteins Sp1 and EGR-1. *J Biol Chem*. 1995;270(38):22500-22506.
  41. Collins S, Wolfraim LA, Drake CG, Horton MR, Powell JD. Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription. *J Immunol*. 2006;177(12):8301-8305.